Precigen is a biopharmaceutical company focused on gene and cell therapies, including engineered immune cell approaches for cancer and other serious diseases. It develops UltraCAR-T and related platforms intended to enable more controlled, multi-gene payloads and potentially simpler manufacturing than traditional CAR-T. The pipeline has centered on oncology and other high-unmet-need indications, building on earlier synthetic biology work under its former Intrexon identity.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0.9 | — | -26.6 | — |
| Q3 2025 | 2.9 | — | -325.3 | — |
| Q4 2025 | 4.6 | — | -23.5 | — |
| Q1 2026 | 23.3 | — | -7.9 | — |
| Q2 2026 | 55 | 6,322.7% | 20.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: RUM Group Inc. (RUM), Lindblad Expeditions Holdings, Inc. (LIND), Central Garden & Pet Company (CENTA), UFP Technologies, Inc. (UFPT), Upstart Holdings, Inc. (UPST), PC Connection, Inc. (CNXN)